Semaglutide Lowers Blood Pressure: Systematic Review and Meta-Analysis
Systematic review confirms subcutaneous semaglutide significantly reduces blood pressure, providing an additional cardiovascular benefit beyond weight and glucose effects.
Quick Facts
What This Study Found
Systematic review confirms subcutaneous semaglutide significantly reduces blood pressure, providing an additional cardiovascular benefit beyond weight and glucose effects.
Key Numbers
Meta-analysis included studies from database inception through July 2024. Used random-effects models to account for variability. Higher baseline blood pressure predicted larger reductions.
How They Did This
Clinical or preclinical study with methodology detailed in the full publication.
Why This Research Matters
This finding has implications for the millions of patients using or considering peptide-based therapies.
The Bigger Picture
This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.
What This Study Doesn't Tell Us
Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.
Questions This Raises
- ?What are the long-term implications of these findings?
- ?How do these results compare to other studies in this area?
- ?What further research is needed to confirm and extend these findings?
Trust & Context
- Key Stat:
- Key finding Systematic review confirms subcutaneous semaglutide significantly reduces blood pressure, providing
- Evidence Grade:
- Evidence grade assessment based on study design and methodology detailed in the full publication.
- Study Age:
- Published in 2025. Reflects current state of peptide therapeutic research.
- Original Title:
- The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.
- Published In:
- Journal of endocrinological investigation, 48(2), 283-294 (2025)
- Authors:
- Ala, Moein, Moheb Aleaba, Mohammadreza
- Database ID:
- RPEP-09833
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What does this study mean for patients?
Systematic review confirms subcutaneous semaglutide significantly reduces blood pressure, providing an additional cardiovascular benefit beyond weight and glucose effects.
How reliable are these findings?
The evidence level depends on study design. Clinical trials provide stronger evidence than case reports. Consult the full publication and discuss with your healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09833APA
Ala, Moein; Moheb Aleaba, Mohammadreza. (2025). The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.. Journal of endocrinological investigation, 48(2), 283-294. https://doi.org/10.1007/s40618-024-02459-3
MLA
Ala, Moein, et al. "The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.." Journal of endocrinological investigation, 2025. https://doi.org/10.1007/s40618-024-02459-3
RethinkPeptides
RethinkPeptides Research Database. "The blood pressure-lowering property of subcutaneous semaglu..." RPEP-09833. Retrieved from https://rethinkpeptides.com/research/ala-2025-the-blood-pressurelowering-property
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.